Small molecule · Inhibitor of IRAK1 and IRAK4 · developed by Rigel Pharmaceuticals
R906289 Monosodium is an oral dual inhibitor of IRAK1 and IRAK4, kinases involved in innate immune signaling. It is being studied in low-risk myelodysplastic syndromes.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05308264 | Phase 1/2 | Low Risk Myelodysplastic Syndromes | Recruiting | RIGL |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Low Risk Myelodysplastic Syndromes
Updated Nov 1, 2026. Something wrong or missing? Report it on the RIGL page.
See RIGL's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
RIGL catalysts and pipeline →